MedPath

Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms

Phase 3
Completed
Conditions
Postmenopausal Symptoms
Registration Number
NCT00727129
Lead Sponsor
Upsher-Smith Laboratories
Brief Summary

The purpose of this study is to compare the safety and efficacy of USL-221 to placebo for postmenopausal patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
495
Inclusion Criteria
  • Postmenopausal women
  • Have moderate to severe hot flashes
  • Normal Pap Smear
Exclusion Criteria
  • Abnormal mammogram
  • Abnormal clinical breast exam
  • BMI >35

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Daily frequency and severity of moderate to severe vasomotor symptoms
Secondary Outcome Measures
NameTimeMethod
vulvar and vaginal atrophy
© Copyright 2025. All Rights Reserved by MedPath